title: Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
abstract: A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and maintain cancer cell proliferation and survival. While most cancers harbor multiple oncogenic mutations, a wealth of preclinical and clinical data supports that many cancers are sensitive to inhibition of single oncogenes, a concept referred to as 'oncogene addiction'. Herein, we describe the clinical evidence supporting oncogene addiction and discuss common mechanistic themes emerging from the response and acquired resistance to oncogene-targeted therapies. Finally, we suggest several opportunities toward exploiting oncogene addiction to achieve curative cancer therapies.
authors: Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
authors: Raymond
authors: R
authors: Pagliarini
authors: Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
authors: Wenlin
authors: W
authors: Shao
authors: Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA william.sellers@novartis.com.
authors: William R
authors: WR
authors: Sellers
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D016503:Drug Delivery Systems / Q000379:methods*; D019008:Drug Resistance, Neoplasm / Q000235:genetics* / Q000502:physiology; D020043:Genes, Essential / Q000235:genetics; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000235:genetics*; D009857:Oncogenes / Q000187:drug effects* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents
keywords: feedback; oncogene addiction; oncogenic shock; targeted therapy